0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Sustained Remission of Membranous Glomerulonephritis after Cyclophosphamide and Prednisone

Frank J. Bruns, MD; Sheldon Adler, MD; Donald S. Fraley, MD; and David P. Segel, MD
[+] Article and Author Information

A portion of this study was presented at the annual meeting of the American Society of Nephrology in December 1988.

Requests for Reprints: Frank J. Bruns, MD, Montefiore-University Hospital, 3459 Fifth Avenue, Pittsburgh, PA 15213.

Current Author Addresses: Drs. Bruns, Adler, Fraley, and Segel: Montefiore-University Hospital, 3459 Fifth Avenue, Pittsburgh, PA 15213.


© 1991 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1991;114(9):725-730. doi:10.7326/0003-4819-114-9-725
Text Size: A A A

Objective: To determine the effect of cyclophosphamide and prednisone on progressive renal failure and on nephrotic features in patients with membranous glomerulonephritis.

Design: Prospective, nonrandomized time series.

Setting: Outpatient clinic at a university medical center.

Patients: Eleven consecutive patients with biopsy-proven membranous glomerulonephritis and rising plasma creatinine levels over at least 6 months.

Intervention: Cyclophosphamide and prednisone in ten patients and cyclophosphamide alone in one patient.

Measurements and Main Results: In ten patients treated with both agents, the median plasma creatinine rose 53 µmol/L (0.6 mg/dL) over the months before treatment from 141 to 194 µmoL/L (1.6 to 2.2 mg/dL) (95% CI, 27 to 141 µmol/L; P = 0.002). After combined therapy for 6 months, the median plasma creatinine fell to 133 µmol/L (1.5 mg/dL) for a median decline of 62 µmol/L (0.7 mg/dL) (CI, 44 to 150 µmol/L; P = 0.006). Pretreatment plasma creatinine levels, which ranged from 159 to 371 µmol/L (1.8 to 4.2 mg/dL), decreased in the ten patients by 6 months and remained stable in seven of the eight patients followed 24 to 54 months after therapy was completed. The median urine protein excretion decreased by 9.6 g/d with 12 months of therapy in the ten patients from 11.9 to 2.3 g/d (CI, 6.0 to 15.1 g/d; P < 0.001). The median plasma albumin rose by 14 g/L from 24 to 38 g/L (CI, 11 to 19 g/L; P < 0.001). The median plasma cholesterol fell by 3.26 µmol/L (140 mg/dL) from 10.45 to 6.52 µmol/L (405 to 252 mg/dL) (CI, 1.42 to 7.16 µmol/L; P = 0.01). One patient who had a relapse 30 months after completing therapy responded to re-treatment with renal function and nephrotic variables returning toward normal. The eleventh patient received cyclophosphamide alone and had a course similar to that of the combined therapy group.

Conclusion: Cyclophosphamide plus prednisone can promote prolonged remissions in membranous glomerulonephritis even when renal function is already declining.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)